ICD-10-CM Billable Code

C93.1

Chronic myelomonocytic leukemia

Clinical Classification Guidelines

Inclusion Terms

  • Chronic monocytic leukemia
  • CMML-1
  • CMML-2
  • CMML with eosinophilia

Code Also

  • , if applicable, eosinophilia (D72.18)

Medical Intelligence & Overview

Chronic myelomonocytic leukemia (CMML) is a rare type of blood cancer that affects the bone marrow, where blood cells are produced. It is classified as a form of leukemia, characterized by an overproduction of monocytes, a type of white blood cell important for fighting infections. CMML progresses slowly compared to other leukemias and is typically diagnosed in adults. The disease is divided into subtypes based on the number of certain cells in the blood and bone marrow, including CMML-1 and CMML-2, with some cases involving eosinophilia, an increased number of eosinophils, another type of white blood cell.

Causes & Symptoms

Clinical Causes: T h e s p e c i f i c c a u s e o f C M M L i s n o t w e l l u n d e r s t o o d . H o w e v e r , v a r i o u s f a c t o r s m a y i n c r e a s e r i s k , i n c l u d i n g : - P r e v i o u s e x p o s u r e t o r a d i a t i o n o r c h e m o t h e r a p y - C e r t a i n g e n e t i c m u t a t i o n s o r i n h e r i t e d c o n d i t i o n s - A h i s t o r y o f o t h e r b l o o d d i s o r d e r s - A g e i n g , a s t h e d i s e a s e p r i m a r i l y a f f e c t s o l d e r a d u l t s - E n v i r o n m e n t a l e x p o s u r e s , s u c h a s c h e m i c a l s o r t o x i n s W h i l e t h e e x a c t c a u s e r e m a i n s u n c e r t a i n , o n g o i n g r e s e a r c h c o n t i n u e s t o e x p l o r e p o s s i b l e r i s k f a c t o r s a s s o c i a t e d w i t h t h e d e v e l o p m e n t o f C M M L .

Key Symptoms: P a t i e n t s w i t h C M M L m a y e x p e r i e n c e a v a r i e t y o f s y m p t o m s , w h i c h c a n d e v e l o p g r a d u a l l y . C o m m o n s i g n s i n c l u d e : - F a t i g u e a n d w e a k n e s s - F e v e r o r r e c u r r e n t i n f e c t i o n s - W e i g h t l o s s a n d l o s s o f a p p e t i t e - E a s y b r u i s i n g o r b l e e d i n g - S w e l l i n g o r p a i n i n t h e a b d o m e n d u e t o a n e n l a r g e d s p l e e n o r l i v e r - S h o r t n e s s o f b r e a t h - P a l e s k i n - N i g h t s w e a t s S i n c e s y m p t o m s c a n b e s i m i l a r t o o t h e r l e s s s e r i o u s c o n d i t i o n s , m e d i c a l e v a l u a t i o n i s e s s e n t i a l f o r a c c u r a t e d i a g n o s i s .

Diagnostic & Treatment

Diagnosis Path: Diagnosing CMML typically involves several steps, including: - Complete blood count (CBC): To detect abnormal levels of white blood cells, monocytes, red blood cells, and platelets - Bone marrow biopsy: To examine the marrow for abnormal cell proliferation and determine the subtype (CMML-1 or CMML-2) - Cytogenetic analysis: To identify genetic mutations or chromosomal abnormalities - Molecular testing: To detect specific gene mutations associated with CMML - Additional tests may include imaging studies to assess organ size and detect possible spread or complications Accurate diagnosis depends on a combination of laboratory findings and clinical evaluation performed by a healthcare professional.

Treatment Protocols: Management of CMML involves several treatment options, tailored to the patient's specific condition and overall health. These may include: - Chemotherapy: To reduce the number of abnormal blood cells - Hypomethylating agents: Such as azacitidine or decitabine, commonly used for CMML treatment - Targeted therapy: Depending on genetic markers - Supportive care: Includes blood transfusions, antibiotics for infections, and growth factors to support blood cell production - Bone marrow or stem cell transplant: The only potential cure, though it is suitable for a limited number of patients due to age and health considerations Regular follow-up and monitoring are critical to managing the disease effectively and adjusting treatment as needed.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is C93.1 a billable ICD-10 code?
Yes, C93.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report C93.1?
Clinical documentation must specify the nature of Chronic myelomonocytic leukemia and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Clinical Meta Tags

chronic leukemia myelomonocytic